Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo
No data about antiretroviral (ARV) treatment coverage and virological response are available among key populations (female sex workers [FSW] and Men having Sex with Men [MSM]) in Togo. This study aimed to both describe Human Immunodeficiency Virus (HIV) immunovirological status and evaluate the pert...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2023-02, Vol.95 (2), p.e28535-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 2 |
| container_start_page | e28535 |
| container_title | Journal of medical virology |
| container_volume | 95 |
| creator | Ferré, Valentine M. Bitty‐Anderson, Alexandra M. Peytavin, Gilles Lê, Minh P. Dagnra, Claver A. Coppée, Romain Gbeasor‐Komlanvi, Fifonsi A. Descamps, Diane Charpentier, Charlotte Ekouevi, Didier K. |
| description | No data about antiretroviral (ARV) treatment coverage and virological response are available among key populations (female sex workers [FSW] and Men having Sex with Men [MSM]) in Togo. This study aimed to both describe Human Immunodeficiency Virus (HIV) immunovirological status and evaluate the pertinence of an original algorithm combining pharmacology (PK) and viral load (VL) to identify subjects at risk of ARV drug resistance. A cross‐sectional multicentric study was conducted in 2017 in Togo. Our PK‐virological algorithm (PK‐VA) defines subjects at risk of resistance when exhibiting both detectable plasma drug concentrations and VL > 200 c/mL. Among the 123 FSW and 136 MSM included, 50% and 66% were receiving ARV, with 69% and 80% of them successfully‐treated, respectively. Genotypes showed drug‐resistance mutation in 58% and 63% of nonvirologically controlled (VL > 200 c/mL) ARV‐treated FSW and MSM, respectively. PK‐VA would have enabled to save 75% and 72% of genotypic tests, for FSW and MSM, respectively. We reported first data about HIV care cascade among key populations in Togo, highlighting they are tested for HIV but linkage to care remains a concern. Furthermore, 70%−80% of ARV‐treated participants experienced virological success. In limited resources settings, where genotyping tests are beyond reach, PK‐VA might be an easiest solution to sort out patients needing ARV adaptation due to resistance. |
| doi_str_mv | 10.1002/jmv.28535 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04000040v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2770479640</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4225-98b839d4264dc7a7d33d66ef3e6e47675c06470f25ab13b4d498a20866477ec83</originalsourceid><addsrcrecordid>eNp10U9v0zAYBnALgVgZHPgCyBIXdsj22nHs-DhNYx0qgsPY1XIdJ3XnxMVOinqCj8Bn5JPg0jEQEhdbevXT4z8PQi8JnBIAerbut6e0rsrqEZoRkLyQIMhjNAPCeME5qY7Qs5TWAFBLSp-io5ILqEGWM_T140rHXpvw49v3rYvBh84Z7bH2XYhuXPV4DHjUsbMjji7d4dDiJk4djja5NOrBWKz7MHRY403YTF6PLgx7Nb--zZluaK0ZbYPv7O4vkLAb8E3ownP0pNU-2Rf3-zH69Pby5mJeLD5cXV-cLwrDKK0KWS_rUjaMctYYoUVTlg3nti0tt0xwURngTEBLK70k5ZI1TNaaQs3zVFhTl8fo5JC70l5tout13KmgnZqfL9R-Bix_T162JNs3B7uJ4fNk06h6l4z1Xg82TElRIYAJyRlk-vofug5THPJL9koyChTEn8NNDClF2z7cgIDaN6hyg-pXg9m-uk-clr1tHuTvyjI4O4Avztvd_5PUu_e3h8if1pCmcQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2779420207</pqid></control><display><type>article</type><title>Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ferré, Valentine M. ; Bitty‐Anderson, Alexandra M. ; Peytavin, Gilles ; Lê, Minh P. ; Dagnra, Claver A. ; Coppée, Romain ; Gbeasor‐Komlanvi, Fifonsi A. ; Descamps, Diane ; Charpentier, Charlotte ; Ekouevi, Didier K.</creator><creatorcontrib>Ferré, Valentine M. ; Bitty‐Anderson, Alexandra M. ; Peytavin, Gilles ; Lê, Minh P. ; Dagnra, Claver A. ; Coppée, Romain ; Gbeasor‐Komlanvi, Fifonsi A. ; Descamps, Diane ; Charpentier, Charlotte ; Ekouevi, Didier K.</creatorcontrib><description>No data about antiretroviral (ARV) treatment coverage and virological response are available among key populations (female sex workers [FSW] and Men having Sex with Men [MSM]) in Togo. This study aimed to both describe Human Immunodeficiency Virus (HIV) immunovirological status and evaluate the pertinence of an original algorithm combining pharmacology (PK) and viral load (VL) to identify subjects at risk of ARV drug resistance. A cross‐sectional multicentric study was conducted in 2017 in Togo. Our PK‐virological algorithm (PK‐VA) defines subjects at risk of resistance when exhibiting both detectable plasma drug concentrations and VL > 200 c/mL. Among the 123 FSW and 136 MSM included, 50% and 66% were receiving ARV, with 69% and 80% of them successfully‐treated, respectively. Genotypes showed drug‐resistance mutation in 58% and 63% of nonvirologically controlled (VL > 200 c/mL) ARV‐treated FSW and MSM, respectively. PK‐VA would have enabled to save 75% and 72% of genotypic tests, for FSW and MSM, respectively. We reported first data about HIV care cascade among key populations in Togo, highlighting they are tested for HIV but linkage to care remains a concern. Furthermore, 70%−80% of ARV‐treated participants experienced virological success. In limited resources settings, where genotyping tests are beyond reach, PK‐VA might be an easiest solution to sort out patients needing ARV adaptation due to resistance.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.28535</identifier><identifier>PMID: 36708093</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Africa ; Algorithms ; Anti-HIV Agents - therapeutic use ; Anti-Retroviral Agents - therapeutic use ; Antiretroviral agents ; ARV resistance ; Cross-Sectional Studies ; Drug resistance ; Drug Resistance, Viral - genetics ; Female ; FSW ; Genotypes ; Genotyping ; HIV ; HIV Infections ; Homosexuality, Male ; Human immunodeficiency virus ; Humans ; Life Sciences ; Male ; Men ; MSM ; Mutation ; Pharmacology ; Populations ; Risk ; Santé publique et épidémiologie ; Sex Workers ; Sexual and Gender Minorities ; Sexually transmitted diseases ; STD ; Togo ; Togo - epidemiology ; Viral Load ; Virology</subject><ispartof>Journal of medical virology, 2023-02, Vol.95 (2), p.e28535-n/a</ispartof><rights>2023 The Authors. published by Wiley Periodicals LLC.</rights><rights>2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4225-98b839d4264dc7a7d33d66ef3e6e47675c06470f25ab13b4d498a20866477ec83</citedby><cites>FETCH-LOGICAL-c4225-98b839d4264dc7a7d33d66ef3e6e47675c06470f25ab13b4d498a20866477ec83</cites><orcidid>0000-0002-2196-6141</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.28535$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.28535$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36708093$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04000040$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Ferré, Valentine M.</creatorcontrib><creatorcontrib>Bitty‐Anderson, Alexandra M.</creatorcontrib><creatorcontrib>Peytavin, Gilles</creatorcontrib><creatorcontrib>Lê, Minh P.</creatorcontrib><creatorcontrib>Dagnra, Claver A.</creatorcontrib><creatorcontrib>Coppée, Romain</creatorcontrib><creatorcontrib>Gbeasor‐Komlanvi, Fifonsi A.</creatorcontrib><creatorcontrib>Descamps, Diane</creatorcontrib><creatorcontrib>Charpentier, Charlotte</creatorcontrib><creatorcontrib>Ekouevi, Didier K.</creatorcontrib><title>Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>No data about antiretroviral (ARV) treatment coverage and virological response are available among key populations (female sex workers [FSW] and Men having Sex with Men [MSM]) in Togo. This study aimed to both describe Human Immunodeficiency Virus (HIV) immunovirological status and evaluate the pertinence of an original algorithm combining pharmacology (PK) and viral load (VL) to identify subjects at risk of ARV drug resistance. A cross‐sectional multicentric study was conducted in 2017 in Togo. Our PK‐virological algorithm (PK‐VA) defines subjects at risk of resistance when exhibiting both detectable plasma drug concentrations and VL > 200 c/mL. Among the 123 FSW and 136 MSM included, 50% and 66% were receiving ARV, with 69% and 80% of them successfully‐treated, respectively. Genotypes showed drug‐resistance mutation in 58% and 63% of nonvirologically controlled (VL > 200 c/mL) ARV‐treated FSW and MSM, respectively. PK‐VA would have enabled to save 75% and 72% of genotypic tests, for FSW and MSM, respectively. We reported first data about HIV care cascade among key populations in Togo, highlighting they are tested for HIV but linkage to care remains a concern. Furthermore, 70%−80% of ARV‐treated participants experienced virological success. In limited resources settings, where genotyping tests are beyond reach, PK‐VA might be an easiest solution to sort out patients needing ARV adaptation due to resistance.</description><subject>Africa</subject><subject>Algorithms</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Antiretroviral agents</subject><subject>ARV resistance</subject><subject>Cross-Sectional Studies</subject><subject>Drug resistance</subject><subject>Drug Resistance, Viral - genetics</subject><subject>Female</subject><subject>FSW</subject><subject>Genotypes</subject><subject>Genotyping</subject><subject>HIV</subject><subject>HIV Infections</subject><subject>Homosexuality, Male</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Men</subject><subject>MSM</subject><subject>Mutation</subject><subject>Pharmacology</subject><subject>Populations</subject><subject>Risk</subject><subject>Santé publique et épidémiologie</subject><subject>Sex Workers</subject><subject>Sexual and Gender Minorities</subject><subject>Sexually transmitted diseases</subject><subject>STD</subject><subject>Togo</subject><subject>Togo - epidemiology</subject><subject>Viral Load</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp10U9v0zAYBnALgVgZHPgCyBIXdsj22nHs-DhNYx0qgsPY1XIdJ3XnxMVOinqCj8Bn5JPg0jEQEhdbevXT4z8PQi8JnBIAerbut6e0rsrqEZoRkLyQIMhjNAPCeME5qY7Qs5TWAFBLSp-io5ILqEGWM_T140rHXpvw49v3rYvBh84Z7bH2XYhuXPV4DHjUsbMjji7d4dDiJk4djja5NOrBWKz7MHRY403YTF6PLgx7Nb--zZluaK0ZbYPv7O4vkLAb8E3ownP0pNU-2Rf3-zH69Pby5mJeLD5cXV-cLwrDKK0KWS_rUjaMctYYoUVTlg3nti0tt0xwURngTEBLK70k5ZI1TNaaQs3zVFhTl8fo5JC70l5tout13KmgnZqfL9R-Bix_T162JNs3B7uJ4fNk06h6l4z1Xg82TElRIYAJyRlk-vofug5THPJL9koyChTEn8NNDClF2z7cgIDaN6hyg-pXg9m-uk-clr1tHuTvyjI4O4Avztvd_5PUu_e3h8if1pCmcQ</recordid><startdate>202302</startdate><enddate>202302</enddate><creator>Ferré, Valentine M.</creator><creator>Bitty‐Anderson, Alexandra M.</creator><creator>Peytavin, Gilles</creator><creator>Lê, Minh P.</creator><creator>Dagnra, Claver A.</creator><creator>Coppée, Romain</creator><creator>Gbeasor‐Komlanvi, Fifonsi A.</creator><creator>Descamps, Diane</creator><creator>Charpentier, Charlotte</creator><creator>Ekouevi, Didier K.</creator><general>Wiley Subscription Services, Inc</general><general>Wiley-Blackwell</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-2196-6141</orcidid></search><sort><creationdate>202302</creationdate><title>Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo</title><author>Ferré, Valentine M. ; Bitty‐Anderson, Alexandra M. ; Peytavin, Gilles ; Lê, Minh P. ; Dagnra, Claver A. ; Coppée, Romain ; Gbeasor‐Komlanvi, Fifonsi A. ; Descamps, Diane ; Charpentier, Charlotte ; Ekouevi, Didier K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4225-98b839d4264dc7a7d33d66ef3e6e47675c06470f25ab13b4d498a20866477ec83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Africa</topic><topic>Algorithms</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Antiretroviral agents</topic><topic>ARV resistance</topic><topic>Cross-Sectional Studies</topic><topic>Drug resistance</topic><topic>Drug Resistance, Viral - genetics</topic><topic>Female</topic><topic>FSW</topic><topic>Genotypes</topic><topic>Genotyping</topic><topic>HIV</topic><topic>HIV Infections</topic><topic>Homosexuality, Male</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Men</topic><topic>MSM</topic><topic>Mutation</topic><topic>Pharmacology</topic><topic>Populations</topic><topic>Risk</topic><topic>Santé publique et épidémiologie</topic><topic>Sex Workers</topic><topic>Sexual and Gender Minorities</topic><topic>Sexually transmitted diseases</topic><topic>STD</topic><topic>Togo</topic><topic>Togo - epidemiology</topic><topic>Viral Load</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ferré, Valentine M.</creatorcontrib><creatorcontrib>Bitty‐Anderson, Alexandra M.</creatorcontrib><creatorcontrib>Peytavin, Gilles</creatorcontrib><creatorcontrib>Lê, Minh P.</creatorcontrib><creatorcontrib>Dagnra, Claver A.</creatorcontrib><creatorcontrib>Coppée, Romain</creatorcontrib><creatorcontrib>Gbeasor‐Komlanvi, Fifonsi A.</creatorcontrib><creatorcontrib>Descamps, Diane</creatorcontrib><creatorcontrib>Charpentier, Charlotte</creatorcontrib><creatorcontrib>Ekouevi, Didier K.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ferré, Valentine M.</au><au>Bitty‐Anderson, Alexandra M.</au><au>Peytavin, Gilles</au><au>Lê, Minh P.</au><au>Dagnra, Claver A.</au><au>Coppée, Romain</au><au>Gbeasor‐Komlanvi, Fifonsi A.</au><au>Descamps, Diane</au><au>Charpentier, Charlotte</au><au>Ekouevi, Didier K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2023-02</date><risdate>2023</risdate><volume>95</volume><issue>2</issue><spage>e28535</spage><epage>n/a</epage><pages>e28535-n/a</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>No data about antiretroviral (ARV) treatment coverage and virological response are available among key populations (female sex workers [FSW] and Men having Sex with Men [MSM]) in Togo. This study aimed to both describe Human Immunodeficiency Virus (HIV) immunovirological status and evaluate the pertinence of an original algorithm combining pharmacology (PK) and viral load (VL) to identify subjects at risk of ARV drug resistance. A cross‐sectional multicentric study was conducted in 2017 in Togo. Our PK‐virological algorithm (PK‐VA) defines subjects at risk of resistance when exhibiting both detectable plasma drug concentrations and VL > 200 c/mL. Among the 123 FSW and 136 MSM included, 50% and 66% were receiving ARV, with 69% and 80% of them successfully‐treated, respectively. Genotypes showed drug‐resistance mutation in 58% and 63% of nonvirologically controlled (VL > 200 c/mL) ARV‐treated FSW and MSM, respectively. PK‐VA would have enabled to save 75% and 72% of genotypic tests, for FSW and MSM, respectively. We reported first data about HIV care cascade among key populations in Togo, highlighting they are tested for HIV but linkage to care remains a concern. Furthermore, 70%−80% of ARV‐treated participants experienced virological success. In limited resources settings, where genotyping tests are beyond reach, PK‐VA might be an easiest solution to sort out patients needing ARV adaptation due to resistance.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36708093</pmid><doi>10.1002/jmv.28535</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-2196-6141</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2023-02, Vol.95 (2), p.e28535-n/a |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04000040v1 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Africa Algorithms Anti-HIV Agents - therapeutic use Anti-Retroviral Agents - therapeutic use Antiretroviral agents ARV resistance Cross-Sectional Studies Drug resistance Drug Resistance, Viral - genetics Female FSW Genotypes Genotyping HIV HIV Infections Homosexuality, Male Human immunodeficiency virus Humans Life Sciences Male Men MSM Mutation Pharmacology Populations Risk Santé publique et épidémiologie Sex Workers Sexual and Gender Minorities Sexually transmitted diseases STD Togo Togo - epidemiology Viral Load Virology |
| title | Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T09%3A54%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmaco%E2%80%90virological%20algorithm%20to%20target%20risk%20of%20drug%20resistance%20among%20a%20population%20of%20HIV%E2%80%90infected%20key%20populations%20in%20Togo&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Ferr%C3%A9,%20Valentine%20M.&rft.date=2023-02&rft.volume=95&rft.issue=2&rft.spage=e28535&rft.epage=n/a&rft.pages=e28535-n/a&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.28535&rft_dat=%3Cproquest_hal_p%3E2770479640%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2779420207&rft_id=info:pmid/36708093&rfr_iscdi=true |